Author Archives: Megan Thomas

#AI #AI / data analytics / healthtech / informatics #Research

AI in drug discovery will be worth $4.05 billion by 2028

The global artificial intelligence (AI) in drug discovery market size is expected to reach US$4.05 billion by 2028 according to a new study by Polaris Market Research. The report “Artificial Intelligence in Drug Discovery Market Share, Size, Trends, Industry Analysis Report, By Therapeutic Area (Oncology, Neurodegenerative Diseases, Cardiovascular Disease, Metabolic Diseases, Infectious Disease,… Read More

#News

#Diagnostics #Events #SLAS 2021

Who is delivering the keynote presentations for SLAS Europe 2021?

The schedule of the upcoming SLAS Europe 2021 Conference & Exhibition from June 23-25 is available to view and registration remains open. Keynote presentations include the opening presentation with Professor Johannes Grillari, Director of the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology. He will cover: ‘From Cellular… Read More

#News

#Cancer research #Data #Events #Immuno-oncology

GSK showcases advances in oncology at ASCO and EHA

GlaxoSmithKline (GSK) will present new data from key focus areas within its oncology portfolio at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (June 4-8) and the European Hematology Association (EHA) 2021 Virtual Congress (June 9-17). The company will present new data on its approved therapies, BLENREP… Read More

#News

#Antibodies #Drug development #Life sciences

Picking the right custom antibody provider

Selecting the right custom antibody provider for a project is an important decision. It can mean the difference between a breakthrough or failure. It is therefore important where and how antibodies are made. With this infographic, available for free download, you will learn what sets Fortis Life Science’s Bethyl… Read More

#Editor's Choice #News

#Clinical trial #Covid-19 #Immunology / Virology & Vaccines #Moderna

Moderna Covid-19 vaccine safe and effective in teens

Moderna has announced that its Phase II/III study of its Covid-19 vaccine (mRNA-1273) in adolescents has met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination. In the study, no cases of Covid-19 were observed in participants who had received two doses of the Moderna Covid-19… Read More

#Covid-19 #News #Trending News

#Clinical trials #Covid-19 #Drug delivery #Drug development #Immunology / Virology & Vaccines #Johnson & Johnson #Vaccines

Janssen single-dose COVID-19 vaccine approved for use in the UK

Johnson & Johnson has announced topline efficacy and safety data from the Phase III ENSEMBLE clinical trial, demonstrating that the investigational single-dose Covid-19 vaccine in development at Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468… Read More

#Covid-19 #News #Trending News

#Epidemiology #Immunology / Virology & Vaccines #Pfizer

Pfizer launches Vaccine Centre of Excellence

Pfizer has launched a Centre of Excellence for Epidemiology of Vaccine-preventable Diseases at the University of Bristol. The centre, which is the second to launch to date and the first outside the US, will be led by Adam Finn, Professor of Paediatrics at Bristol, Director of the Bristol Vaccine Centre… Read More

#News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Royal visit to celebrate key role in vaccine development

Malvern Panalytical, experts in high-precision analytical instruments, welcomed His Royal Highness The Earl of Wessex, Prince Edward, to its Worcestershire headquarters. Malvern Panalytical was selected for the Royal visit, amongst a small number of other Worcestershire businesses, primarily because of its scientific and technical contribution to the development of medicines… Read More

#News #Trending News

#3D modelling #Assay development optimisation & technology #Corning Life Sciences #Drug efficacy #Life sciences

All-in-one solution for the development of 3D liver models

The HepGo Assay-ready 3D Liver Spheroid Kit leverages Corning Life Science’s 3D cell culture technology in liver biology and ADME/Tox. Corning has developed an all-in-one solution for the development of 3D liver models that has been designed to better recapitulate in vivo behaviour. The kit is said to deliver a… Read More

#News

#Biotechnology #Diagnostics #Drug discovery #Immunology #Immunology / Virology & Vaccines #Pandemic

University of Oxford to launch Pandemic Sciences Centre

The University of Oxford has announced the launch of a new centre of global research collaboration and excellence, the Pandemic Sciences Centre. Its mission will be to ensure that the world is better equipped to create global, and equitable science-driven solutions to prepare for, identify, and counter future pandemic threats. Read More

#News #Trending News

#Drug discovery #Infectious diseases #Life sciences #Research

Millions invested to help life sciences fight infectious disease

The UK’s centre for therapeutics innovation, Medicines Discovery Catapult (MDC), has received a £5 million grant to build a Translational Research Facility in Infectious Disease on its Alderley Park site, as part of the government’s Getting Building Fund programme. Actively seeking collaborations with SMEs, academics and others in infectious disease… Read More

#News

#Clinical trial #Covid-19 #Drug development

Covid-19 patients with sepsis one step closer to life-saving treatment

A clinical trial has begun using a human protein called Annexin A5, which is being studied as a potential therapy for Covid-19 patients with sepsis. Annexin A5 is a protein produced inside the human body with unique anti-coagulation (preventing blood clots) and anti-inflammatory properties that could help in the fight… Read More

#News

#Antibodies #Biotherapeutics #Drug discovery #Drug targets #Genovac

Berkeley Lights: Improving antibody discovery

John Proctor, Senior Vice President of Antibody Therapeutics at Berkeley Lights, and Brian Walters, President/CEO of Genovac Antibody Discovery, talk with DDW’s Megan Thomas about the company’s new Beacon system, which the CRO believes may be the new gold standard in antibody discovery with the potential to up antibody discovery. Read More

#Editor's Choice #Exclusive Content #News

#Antibodies #Covid-19 #Research

Critically ill Covid-19 patients have normal antibody production

Researchers at Lawson Health Research Institute (Lawson) and Western University have teamed up with local biotech company, Diagnostics Biochem Canada, to better understand Covid-19 and the body’s immune response to the infection. A recently published study followed 28 critically ill patients at London Health Sciences Centre (LHSC); 14 who tested… Read More

#Covid-19 #News

#Clinical trial #Gastroenterology #Irritable Bowel Syndrome #Pharma

4D pharma new data for treatment of irritable bowel syndrome

4D pharma has released additional positive data from its completed Phase II trial of LBP Blautix in subjects with irritable bowel syndrome with constipation (IBS-C) or with diarrhoea (IBS-D). The data has been presented in a poster session at Digestive Disease Week (DDW), on May 22, 2021, by Professor Eamonn… Read More

#News